These new discoveries as well as our findings suggest a possible clinical translation by targeting KIAA1199 with monoclonal antibody (mAb) or small molecule chemical inhibitor, for treatment of conditions of bone fragility and associated metabolic diseases of obesity and insulin resistance. This evidence concerns the gene CEMIP and Other metabolic disease.